沙美特罗联合噻托溴铵治疗慢性阻塞性肺疾病的效果

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (372 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical significance of treatment of patients with chronic obstructive pulmonary disease (COPD) with seretide combined with spiriva.Methods Sixty patients diagnosed with chronic obstructive pulmonary disease (COPD) and treated between 2013 and 2015 were selected as subjects. Thirty of them received conventional treatment and served as control group while the rest took seretide and spiriva and served as observation group. The clinical efficacy of different intervention programs was compared.Results After treatment, the total effective rate was 83.3% in control group, butwas 96.7% in observation group,and the difference was statistically significant (P<0.05). FEV₁ and FEV₁/FVC of observation group were greater than those of control group, and the difference was statistically significant (P<0.05). After 5 months of treatment,the therapeutic effect was better in observation group than in control group in terms of the 6 min walking distance and quality of life (P<0.05), and the difference was statistically significant.Conclusions In patients with chronic obstructive pulmonary disease (COPD), treatment with seretide combined with spiriva can significantly improve clinical efficacy and recovery of physical functions of patients.

Key words： Sulidie Spiriva chronic obstructive pulmonary disease

Received: 13 July 2016

ZTFLH:

R563

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hualin
	YANG Min
	HOU Yinyu
	and WANG Yu

Cite this article:

WANG Hualin,YANG Min,HOU Yinyu等. Clinical efficacy of seretide combined with spiriva in treatment of patients with chronic obstructive pulmonary disease[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(1): 30-31.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I1/30

[1]	周新锋, 夏晓东. 舒利迭联合噻托溴铵对稳定期中重度慢性阻塞性肺疾病患者肺功能的影响[J]. 中国现代医生, 2015, 53(23):28-30.
[2]	刘建民, 涂强. 慢性阻塞性肺疾病老年患者稳定期联合应用舒利迭和思力华的观察[J]. 江西医药, 2015,50(1):54-56.
[3]	韩辉. 舒利迭联合思力华治疗对稳定期慢性阻塞性肺疾病患者的疗效及肺功能的影响[J]. 实用临床医药杂志, 2016,20(3): 242-245.
[4]	徐胜辉. 思力华联合舒利迭治疗稳定期慢性阻塞性肺病的临床分析[J].当代医学,2015,21(10):153-154.
[5]	李直苹. 舒利迭联合思力华治疗 COPD 临床效果初步评价及分析[J]. 中国实用医药, 2016,8(1):9-10.
[6]	黄富, 梁永祥, 梁健,等. 吉诺通联合舒利迭治疗慢性阻塞性肺疾病急性加重期的临床效果观察[J]. 吉林医学, 2015, 36(4): 623-625.
[7]	代雯文. 西医综合疗法在慢阻肺合并呼竭中的临床效果观察[J]. 世界最新医学信息文摘(连续型电子期刊), 2016, 16(15):1321-1323.
[8]	王晓红, 高颖. 无创呼吸机治疗慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭的疗效观察[J]. 中国药物与临床, 2014,14(1):81-83.